title: Anti-hypertensive effect of chunghyul-dan (qingxue-dan) on stroke patients with essential hypertension.
abstract: Hypertension is one of the modifiable risk factors for stroke. Lowering blood pressure is helpful for primary and secondary prevention of stroke. This study is aimed to assess the efficacy of Chunghyul-dan on stroke patients with stage 1 hypertension using 24 hours ambulatory blood pressure monitoring (24ABPM). Forty hospitalized stroke patients with stage 1 hypertension were included in the study and they were randomly assigned into two groups: group A was treated with Chunghyul-dan 1200 mg once a day for 2 weeks, while group B was not. Twelve subjects were dropped out because of unexpected early discharge or data errors, thus the remaining 28 subjects were included in the final analysis (15 in group A and 13 in group B). Blood pressure was monitored every 30 minutes for 24 hours at baseline and 2 weeks after medication. Blood pressure, pulse rate, trough/peak ratio (TPR) [the value calculated by dividing the blood pressure change at trough (22 to 24 hours after drug intake) by the change at peak (2 adjacent hours with a maximal blood pressure reduction between the second and eighth hour after drug intake)] and smoothness index (SI) (the value calculated as the ratio between the average of the 24 hours, treatment-induced blood pressure changes and its standard deviation) were compared to assess the efficacy of Chunghyul-dan. To assess the safety of Chunghyul-dan, any adverse effects during medication period were monitored. There was no significant difference in the baseline assessment between the two groups. Systolic blood pressure was lower in group A than in group B (141.37+/-8.96 mmHg versus 132.28+/-9.46 mmHg, P = 0.03), while diastolic blood pressure and pulse rate had no significant difference between the two groups. Systolic TPR and SI was 0.87 and 1.04 in group A, respectively. This suggests that Chunghyul-dan have anti-hypertensive effect on stroke patients with stage 1 hypertension.
authors.affiliation: Department of Cardiovascular and Neurologic Diseases (Stroke Center) College of Oriental Medicine, Kyung-Hee University Seoul, Korea. yunpaul@yahoo.co.kr
authors.forename: Sang Pil
authors.initials: SP
authors.lastname: Yun
authors.forename: Woo Sang
authors.initials: WS
authors.lastname: Jung
authors.forename: Scong Uk
authors.initials: SU
authors.lastname: Park
authors.forename: Sang Kwan
authors.initials: SK
authors.lastname: Moon
authors.forename: Chang Nam
authors.initials: CN
authors.lastname: Ko
authors.forename: Ki Ho
authors.initials: KH
authors.lastname: Cho
authors.forename: Young Suk
authors.initials: YS
authors.lastname: Kim
authors.forename: Hyung Sup
authors.initials: HS
authors.lastname: Bae
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D018660:Blood Pressure Monitoring, Ambulatory; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D055502:Secondary Prevention; D020521:Stroke / Q000150:complications / Q000517:prevention & control*; D013599:Systole / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents; C499382:Chunghyuldan; D004365:Drugs, Chinese Herbal